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PGC1α
PPARαFibroblast growth factor 21 (FGF21) is amodulator of energy homeostasis and is increased in humannonalcoholic
liver disease (NAFLD) and after feeding of methionine- and choline-deﬁcient diet (MCD), a conventional inducer
ofmurine nonalcoholic steatohepatitis (NASH). However, the signiﬁcance of FGF21 induction in the occurrence of
MCD-induced NASH remains undetermined. C57BL/6J Fgf21-null and wild-type mice were treated with MCD for
1 week. Hepatic Fgf21mRNA was increased early after commencing MCD treatment independent of peroxisome
proliferator-activated receptor (PPAR) α and farnesoid X receptor. While no signiﬁcant differences in white
adipose lipolysis were seen in both genotypes, hepatic triglyceride (TG) contents were increased in Fgf21-null
mice, likely due to the up-regulation of genes encoding CD36 and phosphatidic acid phosphatase 2a/2c, involved
in fatty acid (FA) uptake and diacylglycerol synthesis, respectively, and suppression of increasedmRNAs encoding
carnitine palmitoyl-CoA transferase 1α, PPARγ coactivator 1α, and adipose TG lipase, which are associated with
lipid clearance in the liver. The MCD-treated Fgf21-null mice showed increased hepatic endoplasmic reticulum
(ER) stress. Exposure of primary hepatocytes to palmitic acid elevated the mRNA levels encoding DNA
damage-inducible transcript 3, an indicator of ER stress, and FGF21 in a PPARα-independent manner, suggesting
that lipid-induced ER stress can enhance hepatic FGF21 expression. Collectively, FGF21 is elevated in the early
stage of MCD-induced NASH likely to minimize hepatic lipid accumulation and ensuing ER stress. These results
provide a possible mechanism on how FGF21 is increased in NAFLD/NASH.
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.1. Introduction
Fibroblast growth factor 21 (FGF21), discovered in 2000, is a protein
consisting of 210 and 209 amino acids in mouse and humans, respec-
tively [1,2]. While FGF21 is mainly synthesized in liver and secreted
into blood, the pancreas, adipose tissue, and stressed muscle may also
be sources of FGF21 production [3–7]. Circulating FGF21 binds to a plas-
ma membrane receptor complex, mainly FGF receptor 1 and β-Klotho,
and enhances expression of glucose transporter 1 in extra-hepatic tis-
sues, such as adipose tissues, leading to improvement of systemic insu-
lin sensitivity [8,9]. Recombinant FGF21 injection markedly decreases
plasma glucose, fatty acid (FA), and triglycerides (TG) in diabetic rhesus
monkeys [10,11], and treatment with LY2405319, a recombinant
variant of FGF21, causes signiﬁcant improvement in dyslipidemia in
obese humans with type 2 diabetes [12]. Therefore, FGF21 is a potent
modulator of glucose/lipid metabolism.
Fgf21 mRNA level is mainly regulated in the liver by several tran-
scription factors associated with energy homeostasis. Peroxisome
proliferator-activated receptor (PPAR) α is a ligand-activated nuclear
receptor expressed in the liver that regulates lipid homeostasis-
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treated with PPARα activators, such asWy-14,643 and ﬁbrates, but not
in similarly-treated Ppara-null mice [14,15]. Additionally, constitutional
levels of hepatic Fgf21mRNA and serum FGF21were signiﬁcantly lower
in Ppara-null mice compared with the wild-type mice [14,15]. These
ﬁndings indicate a critical role for PPARα in regulating FGF21
expression. While fasting and a ketogenic diet are strong physiological
inducers of FGF21 in mice, induction was detected even in Ppara-null
mice to some degree [14,16], thus suggesting that factors other than
PPARαmay contribute to the increase of FGF21 expression. Activation
of farnesoid X receptor (FXR) and protein kinase A signaling can also
up-regulate hepatic FGF21 expression [5,17–19].
Since FGF21 is synthesized in hepatocytes, it is natural to consider
that FGF21 is inﬂuenced by pathological changes in the liver. For
example, hepatic Fgf21 mRNA and serum FGF21 levels were robustly
increased after acetaminophen (APAP) administration in mice, and
co-administration of recombinant FGF21 with APAP ameliorated
hepatotoxicity through attenuating oxidative stress [20]. Additionally,
Fgf21-null mice had an increase in lipopolysaccaride-induced liver
injury and co-treatment of recombinant FGF21 partially improved the
survival [21]. These ﬁndings indicate hepatoprotective properties of
FGF21, but the role of FGF21 induction in chronic liver diseases is incom-
pletely understood.
Nonalcoholic fatty liver disease (NAFLD) is one of the major causes
of persistent liver abnormalities increasing worldwide. Due to excess
calorie intake and sedentary lifestyle, surplus lipids are stored in hepa-
tocytes, a condition designated as hepatic steatosis. Nonalcoholic
steatohepatitis (NASH)may develop through increasing hepatic inﬂam-
mation and/or hepatocyte damage to steatotic liver, leading to hepatic
ﬁbrosis, hepatocellular carcinoma, and eventually death [22–24].
Hepatic Fgf21 mRNA and serum FGF21 are elevated in human NAFLD
and correlated with the degree of steatosis [25–28], but themechanism
by which FGF21 is induced in steatotic hepatocytes and its role in
hepatic steatosis are not known.
Treatment with a methionine- and choline-deﬁcient diet (MCD) is a
conventional and usefulmodel to induceNASH in rodents.While hepat-
ic Fgf21mRNA and serum FGF21 were robustly increased after 2-week
MCD feeding [29], the signiﬁcance of FGF21 induction in the early
stage ofMCD-inducedNASH (MCD-NASH) remains unclear. In the pres-
ent study, MCD was used to treat Fgf21-null and wild-type mice for
1 week and the phenotypical changes were examined. The livers of
Fgf21-null mice revealed greater TG accumulation and endoplasmic
reticulum (ER) stress compared with their wild-type counterparts in
the early stage of MCD-NASH. In vitro studies using mouse primary
hepatocytes uncovered that ER stress and oxidative stress augmented
the mRNA levels of Fgf21. Additionally, treatment of mouse primary
hepatocytes with palmitic acid (PA) induced the expression of Fgf21 in
a PPARα-independent manner, and the increase was likely associated
with increased DNA damage-inducible transcript 3 (Ddit3, also desig-
nated as CHOP), a typical indicator of ER stress. Collectively, FGF21
was induced in the early stage of MCD-NASH in response to lipid
accumulation likely in order to moderate lipid-derived ER stress.
These results shed new insights into the physiological role of FGF21
and a possible mechanism of FGF21 induction in the pathogenesis of
NAFLD/NASH.
2. Methods
2.1. Mice and treatment
All studies were conducted according to Institute of Laboratory
Animal Resource guidelines and approved by the National Cancer
Institute Animal Care and Use Committee. The mice were housed in a
speciﬁc pathogen-free environment controlled for temperature and
light (25 °C, 12-h light/dark cycle) and maintained with NIH31 regular
chow and tap water ad libitum. The MCD was purchased fromDyets Inc. (#58810; Bethlehem, PA) and methionine- and choline-
supplemented MCD diet (MCS, #518754; Dyets) was used as a control
diet. The compositions of these diets were described previously
[29,30]. Before starting the experiments, regular chow was replaced
with MCS for acclimatization. After acclimatization for 3–5 days, the
mice were weighed and moved to new cages and the respective diet
was given. To check the expression of Fgf21 mRNA, 8- to 12-week-old
male C57BL/6NCr mice were treated with MCD or control MCS for
1 week (n = 7–8/group) and the liver, epididymal, inguinal, and
perirenal white adipose tissue (WAT), and interscapular brown adipose
tissue (BAT) harvested. Additionally, 16- to 18-week-old male C57BL/
6NCr mice were similarly treated with MCD or control MCS for 1 week
(n = 6–9/group), and mRNA levels in liver and pancreas measured.
Liver samples of mice after 3-day, 1-week, and 2-week MCD treatment
used in a previous study [30] were also examined as the time-course
assay (n = 5/group). In order to investigate the contribution of PPARα
and FXR to the hepatic Fgf21 mRNA induction, MCD or control MCS
was fed to male 8- to 12-week-old wild-type, Ppara-null, and Fxr-null
mice for 2 weeks (n = 4–5/group). To determine the signiﬁcance of
FGF21 induction in the occurrence of MCD-NASH, MCD or MCS was
given to male 6- to 10-week-old wild-type or Fgf21-null mice on
C57BL/6J genetic background [31] for 1 week (n = 5/group). In all
experiments, mice were weighed and killed after a 6-h fasting. Blood
was collected using Serum Separator Tubes (Becton, Dickinson and
Company, Franklin Lakes, NJ) and centrifuged for 10 minutes at
8,000 g at 4 °C for obtaining serum. Liver and epididymal WAT were
harvested, weighed, and divided into the two parts. One part of these
tissues was immediately soaked in 10% neutral formalin for histological
examination. Sera and the remaining tissues were immediately frozen
in liquid nitrogen and kept at−80 °C until use.
2.2. Isolation and treatment of mouse primary hepatocytes
Mouse primary hepatocytes were isolated from C57BL/6NCr wild-
type and Ppara-null mice at the age of 8 to 12 weeks [32]. Brieﬂy, the
abdomen was incised under anesthesia and mesentery and intestine
were moved to expose the portal vein. A cannula was inserted into
the portal vein and liver was perfused with 40 ml of Hank's buffered
salt solution (HBSS) without magnesium or calcium (Gibco, Carlsbad,
CA) containing 1 mM EDTA at 4 ml/min. Blood was extravasated by
cutting the inferior vena cava. After perfusion of the entire liver using
50 ml of HBSS containing collagenase I and II (0.6 mg/ml each, Gibco)
and calcium chloride dehydrate (5 mM) at the speed of 6 ml/min, the
digested liver was removed and placed in a sterile 10-cm Petri dish
with 0.01 M phosphate-buffered saline (PBS). The hepatic capsule was
torn by ﬁne-tip forceps and dispersed cells were ﬁltered through 70-
μmcell strainer (BD Biosciences, Sparks,MD) into a 50-ml tube and cen-
trifuged at 1000 rpmat 4 °C for 3min. Hepatocyteswere furtherwashed
and puriﬁed by gradient centrifugation using Percoll (GE Healthcare,
Piscataway, NJ). After washing with PBS and trypan blue staining, the
number of hepatocytes were counted and then seeded in collagen-
coated 12-well plates (BD Biosciences) at a density of 3 × 105 cells/well.
Primary hepatocytes were cultured in RPMI 1640 medium (Lonza, Basal,
Switzerland) with 10% fetal bovine serum, 2 mM glutamine, and antibi-
otics (100 U/ml penicillin and 100 μg/ml streptomycin) and treatment
started 4–6 h after seeding. To induce ER stress, cells were incubated in
RPMI medium containing DMSO (vehicle) or thapsigargin (250 and 500
nM, Sigma-Aldrich, St. Louis, MO) and harvested 6 h after treatment. To
induce oxidative stress, cells were incubated in RPMI medium containing
sterile distilled water (vehicle) or hydrogen peroxide (H2O2, 150 and
300 μM, Sigma-Aldrich) and harvested 4 h after treatment [30]. To deter-
mine the response to pro-inﬂammatory cytokines, cellswere treatedwith
RPMI medium containing tumor necrosis factorα (TNFα, 100 ng, Sigma-
Aldrich) or the same volume of sterile distilledwater for 24 h as described
previously [30]. PA and oleic acid (OA), purchased from Sigma-Aldrich,
were dissolved in isopropanol at a stock concentration of 40 mM and
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the methods detailed in previous studies [33,34]. Cells were incubated
in RPMI medium containing vehicle, PA (400 μM), or OA (400 μM) and
harvested 16 h after treatment. Period of treatment and concentrations
of the agents were determined according to cell viability assessed in pre-
liminary experiments. Harvested cellswere subjected to determination of
mRNA levels.
2.3. mRNA analysis
The mRNA levels were measured by quantitative polymerase chain
reaction (qPCR). Total RNA was extracted using a TRIzol Reagent
(Invitrogen, Carlsbad, CA) and cDNA was generated from 1 μg RNA
with a SuperScript II™ Reverse Transcriptase kit and random oligonu-
cleotides (Invitrogen). Quantitative PCR was performed using SYBR
green PCRmastermix andABI Prism7900HT SequenceDetection System
(Applied Biosystems, Foster City, CA) [29,30]. The primer pairs were
designed using qPrimerDepot (http://mouseprimerdepot.nci.nih.gov/)Fig. 1. PPARα-independent induction of FGF21 in the early stage of MCD-NASH. (A) Expression
Male 8- to 12-week-old C57BL/6NCr wild-type mice were fed a methionine- and choline-deﬁ
1 week (n = 7–8/group). The mRNA levels in each tissue were expressed as fold change relat
in another mouse set. Male 16- to 18-week-old C57BL/6NCr wild-type mice were fed a MCD
fold change relative to those of MCS-treated mice. (C) Time course of hepatic Fgf21mRNA in
MCS for 3 days, 1 week, and 2 weeks (n = 5/group). The mRNA levels of each time point we
independent induction of Fgf21 by MCD treatment. Male 8- to 12-week-old wild-type, Ppara-nu
were expressed as fold change relative to those of MCS-treated wild-type mice. Statistical ana
treated mice.and listed in Supplementary Table 1. The mRNA levels were normalized
to those of 18S ribosomal RNA and expressed as fold change relative to
those of control wild-type mice.
2.4. Histological analysis
Small pieces of liver tissue and epididymal WAT were ﬁxed in 10%
neutral formalin, dehydrated by serial ethanol/xylene, and embedded
in parafﬁn. Sections (4-μm thick) were stained by the hematoxylin
and eosin method [30] and were evaluated in a blinded manner.
2.5. Biochemical analysis
Serum alanine aminotransferase (ALT) concentrations were mea-
sured with an assay kit for ALT (Catachem, Bridgeport, CT) [29,30].
Hepatic TG contents were determined as described previously [29,30]
using a kit purchased from Wako Chemicals USA, Inc. (Richmond, VA).
For assessment of hepatic oxidative stress, mitochondrial fractionsof Fgf21mRNA in the liver and white/brown adipose tissue (WAT and BAT, respectively).
cient diet (MCD) or control methionine- and choline-supplemented MCD diet (MCS) for
ive to those of MCS-treated mice. (B) Expression of Fgf21mRNA in the liver and pancreas
or MCS for 1 week (n = 6–9/group). The mRNA levels in each tissue were expressed as
duction. Male 8- to 12-week-old C57BL/6NCr wild-type mice were fed a MCD or control
re expressed as fold change relative to those of MCS-treated mice. (D) PPARα- and FXR-
ll, and Fxr-null mice were fed a MCD or control MCS for 2 weeks (n= 4–5/group). Values
lysis was performed using the Student's t-test. *P b 0.05, **P b 0.01, ***P b 0.001 vs. MCS-
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PeroxiDetectTM Kit (Sigma-Aldrich). Measurement of protein concen-
trations was carried out using BSA™ protein assay kit (Thermo Scientif-
ic, Rockford, IL).
2.6. Immunoblot analysis
Immunoblot analysis of hormone-sensitive lipase (HSL) and adipose
TG lipase (ATGL) was performed as described previously [35]. Brieﬂy,
approximately 40 mg of epididymal WAT was homogenized in RIPA
buffer containing a proteinase inhibitor cocktail. The homogenates
were centrifuged at 10,000g for 10 min at 4 °C to obtain lipid-free
cytosolic extracts. Cytosolic extracts (30 μg of protein) were subjected
to sodium dodecyl sulfate-polyacrylamide gel electrophoresis and
transferred to polyvinylidene diﬂuoride membranes. The membranes
were blocked with 5% bovine serum albumin or skimmilk and incubat-
ed overnight with primary antibodies against HSL (Cell Signaling
Technology, Inc., Danvers,MA, #4107, 1:1000 dilution), phosphorylated
HSL (Cell Signaling, #4139, 1:1000 dilution), ATGL (Cell Signaling,
#2439, 1:1000 dilution), and phosphorylatedATGL (Abcam, Cambridge,
MA, #135093, 1:1000 dilution). Afterwashing, the blotswere incubated
with peroxidase-conjugated goat anti-rabbit IgG (Cell Signaling, #7074,
1:3000 dilution) and scanned. The β-actin band was obtained byFig. 2. Similar body weight loss after 1-week MCD treatment in Fgf21-null mice. Male 6- to
methionine- and choline-deﬁcient diet (MCD) or control methionine- and choline-supplem
normalized to those of MCS-treated WT mice. (B) Body weight (BW) changes during treatmen
relative to BW just before initiating the MCD or MCS treatment. (D) Daily food intake. (E) We
the ANOVA test with Bonferroni's correction. #P b 0.05, ###P b 0.001 vs. MCS-treated mice in thre-probing the membranes with antibody against β-actin (Abcam,
#8227, 1:10,000 dilution) that was used as a loading control.
2.7. Determination of hepatic diacylglycerol (DAG) contents
Approximately 25mgof liver tissuewashomogenized in 300 μl H2O/
400 μl methanol. The homogenates were added to 800 μl of chloroform,
incubated at 37 °C while shaking for 20 min, and then centrifuged at
10,000g for 20 min. Organic phases were collected, dried, and
reconstituted with 100 μl of 1:1 methanol/chloroform. After 50-fold
dilution with injection buffer (isopropanol:acetonitrile:H2O = 2:1:1),
samples were subjected to mass spectrometry (MS) analysis. The sam-
ples (5 μl) were separated by reverse phase HPLC using a Prominence
20 UFLCXR system (Shimadzu, Columbia, MD) with a Waters (Milford,
MA) CSH C18 column (100 mm × 2.1 mm, 1.7 μm particle size) main-
tained at 55 °C and a 20min aqueous/acetonitrile/isopropanol gradient,
at a ﬂow rate of 225 μl/min. Solvent A was 40% water, 60% acetonitrile
with 10 mM ammonium formate, and 0.1% formic acid, and Solvent B
was 90% isopropanol, 10% acetonitrile with 10mMammonium formate,
and 0.1% formic acid. The initial conditionwas 60% A and 40% B, increas-
ing to 43% B at 2 min, 50% B at 2.1 min, 54% B at 12 min, 70% B at
12.1 min and 99% B at 18 min, and held at 99% B until 20 min before
returning to the initial conditions. The eluate was delivered into a10-week-old C57BL/6J wild-type (WT) and Fgf21-null (KO) mice were treated with a
ented MCD diet (MCS) for 1 week (n = 5/group). (A) Fgf21 mRNA levels. Values were
t. (C) BW changes at the end of the treatment. Values were expressed as the percentage
ights of epididymal white adipose tissue (WAT). Statistical analysis was performed using
e same genotype. NS, not signiﬁcant.
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Framingham, MA). The capillary voltage was set at 5.5 kV in positive
ionmode and 4.0 kV in negative ionmodewith a declustering potential
of 80 V used in bothmodes. Themass spectrometerwas operated in IDA
(Information Dependent Acquisition) mode with a 100 ms survey scan
from 100 to 1200m/z, and up to 20 MS/MS product ion scans (100 ms)
per duty cycle using a collision energy of 50Vwith a 20V spread. Hepatic
DAG levels were calculated as the sum of DAG 36:1, 36:2, and 36:3,
normalized by liver weight, and expressed as fold change relative to
those of control wild-type mice.
2.8. Determination of hepatic ceramide contents
Ceramide quantiﬁcationwas carried out as described previously [36]
using a Waters Xevo TQ-S triple quadrupole MS system with an
Acquity™ I-class UPLC (Waters Corp., Milford, MA). For UPLC, a mixture
of A-water, B-acetonitrile/isopropanol (5/2), both containing 10 mM
ammonium acetate and 0.1% formic acid was used. Initial 70% A for
1 min, followed by a linear gradient to 50% A at 3 min, to 1% A at
8 min, held until 15 min, returned to the initial conditions over 1 min,
and then held for an additional 2 min for column equilibration. The
ﬂow rate was 0.4 ml/min and column temperature was maintained at
50 °C. A Waters Xevo TQ-S was operated in MRMmode, with capillary
2.2 kV, source temperature of 150 °C, desolvation gas ﬂow of 850 L/h
at 450 °C. The total run time was 18 min, and the cone voltage and
collision energy for each of the MRM transitions was determined
using Waters IntelliStart™ software.Fig. 3. Similarwhite adipose lipolysis after 1-weekMCD treatment in Fgf21-nullmice. Epididyma
wild-type mice; KO, Fgf21-null mice. (A) Representative histological appearance of epididy
phosphorylated and total hormone-sensitive lipase (p-HSL and HSL, respectively) and adipo
WAT (30 μg of protein) were loaded in eachwell. The β-actin bandwas used as a loading contr
sition of HSL and ATGL bands.2.9. Statistical analysis
Quantitative datawere expressed asmean±SEM. Statistical analyses
were performed using the two-tailed Student's t-test between the two
groups, the ANOVA test with Bonferroni's correction among themultiple
groups, and the Dunnet's test among the three primary hepatocyte
groups, respectively. A p value of less than 0.05 was considered to be
statistically signiﬁcant.
3. Results
3.1. Fgf21 mRNA is increased in the early stage of MCD-NASH independent
of PPARα and FXR
MCD treatment for 1 week increased Fgf21mRNA levels in liver, but
not in epididymal, inguinal, and perirenal WAT and BAT (Fig. 1A). Fgf21
mRNA was marginally increased in the pancreas after 1 week of MCD
treatment, but the increase did not reach statistical signiﬁcance
(Fig. 1B). Increased Fgf21 mRNA was found up to 3 days after starting
MCD treatment (Fig. 1C). Hepatic Fgf21mRNA levels were signiﬁcantly
reduced in Ppara-null mice compared with wild-type mice on the
control diet (approximately 10% of wild-type mice), indicating a major
contribution of PPARα to constitutive FGF21 expression. However, the
induction of hepatic Fgf21mRNA by MCD feeding was also detected in
Ppara-null and Fxr-null mice (Fig. 1D). These results revealed that
FGF21 induction in the liver is an early event in MCD-NASH develop-
ment but occurs independent of PPARα and FXR signaling.lwhite adipose tissue (WAT)was examined in the samemouse set presented in Fig. 2.WT,
mal WAT. Hematoxylin and eosin staining, bar = 100 μm. (B) Immunoblot analysis of
se triglyceride lipase (p-ATGL and ATGL, respectively). Cytosolic extracts of epididymal
ol. EpididymalWAT isolated from a 36 h-fastedmouse was used for detecting the true po-
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are not associated with increased FGF21
Body weight (BW) loss and WAT lipolysis appear early after com-
mencing MCD treatment [29]. Since previous studies implied a pro-
moting effect for FGF21 on WAT lipolysis [10,14], anthropometric
parameters and WAT phenotypes were examined in Fgf21-null mice
after 1 week of MCD treatment. Hepatic Fgf21 mRNA was robustly
increased after MCD treatment but was not detected in Fgf21-null
mice (Fig. 2A). BW changes, food intake, and epididymal WAT mass
were not statistically different between MCD-fed wild-type and Fgf21-
null mice (Fig. 2B–E). Histological appearance of epididymal WAT
exhibited a reduction in adipocyte size in both genotypes after MCD
treatment (Fig. 3A). Consistently, immunoblot analysis revealed a
marked increase in phosphorylated HSL and ATGL in both genotypes
by MCD feeding (Fig. 3B); there were no signiﬁcant changes in the
expression of HSL and ATGL between wild-type and Fgf21-null mice
(Fig. 3B). These results suggest that the enhanced WAT lipolysis after
the MCD treatment is not linked with increased FGF21.
3.3. Fgf21-null mice showmore severe TG accumulation by MCD treatment
There were no differences in serum ALT concentrations and levels of
TnfmRNA, encoding TNFα, and Cd68mRNA, which are associated with
hepatic inﬂammation, between the two treated groups (Fig. 4A and C).
However, hepatic TG contentswere greater in Fgf21-null mice comparedFig. 4.More severe hepatosteatosis in Fgf21-null mice after 1-weekMCD treatment. Liver sampl
mice; KO, Fgf21-null mice. (A) Serum alanine aminotransferase (ALT) levels. (B) Representativ
magniﬁcation) or 100 μm (×200 magniﬁcation). (C) qPCR analysis of genes associated wit
(D) Hepatic triglyceride (TG) contents. Statistical analysis was performed using the ANOV
##P b 0.01, ###P b 0.001 vs. MCS-treated mice in the same genotype. NS, not signiﬁcant.with the wild-type counterparts after the MCD treatment (Fig. 4D).
Histologically, more severe steatosis was found in MCD-treated
Fgf21-null mice (Fig. 4B).
To examine the mechanism of severe TG accumulation in these mice,
the levels of mRNAs encoded by genes involved in FA metabolism were
measured. Increases in Cd36 mRNA, encoding transporter that has an
important role in FA uptake from blood into hepatocytes and is down-
regulated by FGF21 [9], were noted in MCD-treated Fgf21-null mice
compared with wild-type mice (Fig. 5A). Carnitine palmitoyl-CoA trans-
ferase 1α (Cpt1a) mRNA, encoding the ﬁrst enzyme in mitochondrial
β-oxidation, was increased in MCD-fed wild-type mice compared with
MCS-fed wild-type mice, but this increase was not observed in Fgf21-
null mice after MCD feeding (Fig. 5B). There were no signiﬁcant differ-
ences in the mRNAs encoding enzymes associated with FA synthesis,
such as fatty acid synthase (Fasn), acetyl-CoA carboxylase α (Acaca),
and stearoyl-CoA desaturase 1 (Scd1) between the four mouse groups
(Fig. 5C). However, MCD-induced down-regulation of Scd1mRNA was
apparently milder in the Fgf21-null mice compared with wild-type mice
(P= 0.035 calculated by means of Student's t-test, MCD-fed wild-type
mice vs.MCD-fed Fgf21-nullmice),which is in agreementwith a previous
observation that FGF21 suppresses SCD1 expression in the liver [9].
TG and its precursor DAG are glycerolipids generated from
phosphatidate. ThemRNA levels of genes associatedwith phosphatidate-
DAG-TGmetabolismwere also determined. The phosphatidate phospha-
tase 2a and 2c (Ppap2a/2c) mRNAs, involved in DAG synthesis, were in-
creased in MCD-treated Fgf21-null mice compared with wild-type micees were examined in the samemouse set presented in Fig. 2 (n= 5/group).WT,wild-type
e histological appearance of liver. Hematoxylin and eosin staining, bar = 200 μm (×100
h inﬂammation. The mRNA levels were normalized to those of MCS-treated WT mice.
A test with Bonferroni's correction. *P b 0.05 between MCD-treated WT and KO mice.
Fig. 5. qPCR analysis of genes associated with fatty acid metabolism. Liver samples obtained frommice used in Fig. 2 were subjected to qPCR analysis (n= 5/group). The mRNA levels of
genes involved in fatty acid (FA) uptake and activation (A),mitochondrialβ-oxidation (B), and FA synthesis (C)weremeasured. Valueswerenormalized to those ofMCS-treatedwild-type
(WT) mice. KO, Fgf21-null mice. Statistical analysis was performed using the ANOVA test with Bonferroni's correction. *P b 0.05 between MCD-treated WT and KO mice. #P b 0.05,
###P b 0.001 vs. MCS-treated mice in the same genotype. NS, not signiﬁcant.
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mRNAs, TG-synthesizing enzymes, was not changed between the geno-
types (Fig. 6A and data not shown). Additionally, Pnpla2mRNA encoding
ATGL, a major TG-hydrolyzing enzyme in the liver, was increased in
MCD-fed wild-type mice compared with MCS-fed wild-type mice, but
the increase was not seen in the Fgf21-null groups (Fig. 6B). Hepatic con-
tents of DAG and ceramides, active intermediate lipids in FA/glycerolipid
cycling, were not different between MCD-treated wild-type and Fgf21-
null mice (Supplementary Fig. 1).
Among the transcription factors regulating hepatic FA/TG metabo-
lism, greater increases in PPARγ1 (Pparg1) mRNA levels were observed
in MCD-treated Fgf21-null mice (Fig. 6C). Interestingly, Ppargc1amRNA
levels encoding PPARγ co-activator 1α (PGC1α), which enhances mito-
chondrial β-oxidation activity, were increased in MCD-fed wild-type
mice, but no increase was found in similarly-treated Fgf21-null mice
(Fig. 6C). The expression of Ppara was similar between the genotypes
(Fig. 6C). Overall, increased hepatic TG contents in MCD-treated Fgf21-
null mice were likely due to up-regulation of Cd36 and Ppap2a/2c and
suppression of increased Cpt1a, Pnpla2, and Ppargc1a. While FGF21 did
not affect the expression of inﬂammation-related genes and serum
ALT levels in the early stage of MCD-NASH, it played an important role
in attenuating hepatic lipid accumulation.
3.4. Fgf21-null mice demonstrate greater ER stress by MCD treatment
Since oxidative stress and ER stress are key components of the path-
ogenesis of NASH [22–24], these factors were assayed. The levels of
mitochondrial H2O2 were increased by MCD treatment, but there
were no signiﬁcant differences between the genotypes (Fig. 7A). The
levels of NADPH oxidase 2 (Cybb) and superoxide dismutase 2 (Sod2)
mRNAs encoding reactive oxygen species-generating and -eliminatingenzyme, respectively, were also similar between the two groups given
the MCD (Fig. 7B). However, the Ddit3, heat shock protein 5 (Hspa5),
and tumor necrosis factor receptor superfamily member 10b (Tnfrsf10b)
mRNAs, representative genes induced by ER stress and ensuing apoptosis,
were signiﬁcantly increased in MCD-treated Fgf21-null mice (Fig. 7C).
3.5. PA induces ER stress and FGF21 in mouse primary hepatocytes
The direct association between FGF21 induction, ER stress, and lipid
accumulation was explored using mouse primary hepatocytes. Treat-
ment with thapsigargin, a conventional ER stress inducer, augmented
Fgf21mRNA (Fig. 8A). PA, but not OA, was reported to induce ER stress
leading to lipotoxicity in hepatocytes and pancreatic β cells [33,34,37].
Treatment of primary hepatocytes with 400 μM of PA elevated Ddit3
and Fgf21mRNA levels, but treatment with the same concentrations of
OA did not (Fig. 8B and C). PA-induced increases in Fgf21mRNA were
detected even in primary hepatocytes isolated from Ppara-null mice
(Fig. 8D). These results suggest that PA induces FGF21 in a PPARα-
independent manner likely through enhancing ER stress.
3.6. Oxidative stress, but not TNFα, induces FGF21 in mouse primary
hepatocytes
Lastly, the contribution of oxidative stress and inﬂammatory signal-
ing to FGF21 induction was assessed. Treatment of primary hepatocytes
with H2O2 increased the mRNA levels of Egr1 encoding early growth
response 1 (EGR1), a rapidly-induced transcription factor in response
to oxidative stress, and Fgf21 in a dose-dependent and PPARα-
independentmanner (Fig. 9A and B). However, treatmentwith TNFαde-
creased the Fgf21 expression (Fig. 9C). These results indicate that FGF21
is induced in response to cellular stresses, rather than TNFα signaling.
Fig. 6.qPCR analysis of genes associatedwith glycerolipidmetabolism and transcription factors. The same cDNA samples used in Fig. 5were used (n=5/group). ThemRNA levels of genes
associated with triglyceride (TG) synthesis (A), TG secretion or hydrolysis (B), and genes encoding transcription factors (C) were measured. Values were normalized to those of MCS-
treated wild-type (WT) mice. KO, Fgf21-null mice. Statistical analysis was performed using the ANOVA test with Bonferroni's correction. *P b 0.05, **P b 0.01, ***P b 0.001 between
MCD-treated WT and KO mice. #P b 0.05, ##P b 0.01, ###P b 0.001 vs. MCS-treated mice in the same genotype. NS, not signiﬁcant.
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The present study aimed to explore the role of FGF21 inMCD-NASH.
Disruption of Fgf21 in mice revealed signiﬁcant increases in hepatic
TG and ER stress one week after the MCD treatment. More severe TG
accumulation in MCD-fed Fgf21-null mice was likely due to increasedFig. 7. Greater ER stress in Fgf21-null mice after 1-week MCD treatment. Liver samples in the s
mice; KO, Fgf21-null mice. (A) Mitochondrial H2O2 contents. (B and C) qPCR analysis of genes
of MCS-treated WT mice. Statistical analysis was performed using the ANOVA test with Bonf
mice. ##P b 0.01, ###P b 0.001 vs. MCS-treated mice in the same genotype. NS, not signiﬁcant.expression of Cd36 and Ppap2a/2c and suppression of Cpt1a and
Pnpla2 expression. Increased Fgf21 by PAwas associated with increased
Ddit3, but not PPARα activation, in primary hepatocytes. Thus, FGF21
was induced in response to toxic lipid accumulation in the early
stage of MCD-NASH possibly to attenuate lipid-derived ER stress
(i.e., lipotoxicity). These results demonstrate a critical role for FGF21ame mouse set presented in Fig. 2 were subjected to assay (n = 5/group). WT, wild-type
associated with oxidative stress (B), and ER stress (C). Values were normalized to those
erroni's correction. *P b 0.05, **P b 0.01, ***P b 0.001 between MCD-treated WT and KO
Fig. 8. Palmitate induces Fgf21 independent of PPARα inmouse primary hepatocytes. (A) Thapsigargin induces ER stressmarkerDdit3 and Fgf21mRNAs.Mouse primary hepatocyteswere
treated with vehicle (Veh) or thapsigargin (Thap, 250 or 500 nM) for 6 h. Statistical analysis was carried out using the Dunnet's test. n = 3–4/group. *P b 0.05, **P b 0.01, ***P b 0.001 vs.
vehicle-administered hepatocytes. (B and C) Palmitate (PA), but not oleate (OA), inducesDdit3 and Fgf21mRNAs.Mouse primary hepatocyteswere treatedwith vehicle (Veh) or the fatty
acid (400 μM) for 16 h. Statistical analysis was conducted using the Student's t-test. n = 4–6/group. *P b 0.05, **P b 0.01 vs. vehicle-administered hepatocytes. (D) PPARα-independent
induction of Fgf21mRNA by PA. The same experiment as panel (B) was performed using primary hepatocytes isolated from Ppara-null mice. Statistical analysis was conducted using
the Student's t-test. n = 4/group. *P b 0.05 vs. vehicle-administered hepatocytes.
1250 N. Tanaka et al. / Biochimica et Biophysica Acta 1852 (2015) 1242–1252in the control of hepatic lipid homeostasis and cellular stress in the
context of NAFLD/NASH.
The role of FGF21 on WAT lipolysis is controversial. While some
studies reported that FGF21 inhibits lipolysis [38,39], others showed
that Fgf21-overexpressing mice had smaller white adipocytes and
higher lipolysis activity comparedwithwild-typemice [14]. Additional-
ly, treatment of 3T3-L1 adipocytes with FGF21 induced lipolysis [10],
and administration of recombinant FGF21 to mice and monkeys caused
reductions in BW and WAT mass [10,11]. In a previous study, elevated
Fgf21 mRNA levels in the liver, increased circulating FGF21, and
enhanced WAT lipolysis were found within 2 weeks after commencing
MCD treatment [29]. Since WAT lipolysis may promote the develop-
ment of hepatic steatosis and steatohepatitis [29,40], these observations
led to the hypothesis that FGF21 affects the occurrence of MCD-NASH
through accelerating WAT lipolysis. However in this study, the extent
of WAT lipolysis in MCD-treated Fgf21-null mice was similar to wild-
type counterparts, suggesting only minor contribution of FGF21 to
MCD-induced adipose lipolysis. Recent studies revealed that FGF21 is
associated with browning of white adipocytes [41], but a preliminary
evaluation found no induction of uncoupling protein 1 and carboxyl
ester lipase, typical BAT-speciﬁc genes downstream of FGF21 [14],
respectively, in the WAT of MCD-treated mice (data not shown). These
ﬁndings may support the WAT changes observed in the present study.
The livers of MCD-fed Fgf21-null mice exhibited lower Cpt1a and
Ppargc1a mRNA levels; these mRNAs encode proteins related to mito-
chondrial β-oxidation activity, thus indicating delayed FA degradation
compared with wild-type mouse livers. This is consistent with the re-
cent observation that hepatic free FA contents were increased and PA
degradation in mitochondria (i.e., mitochondrial β-oxidation activity)
was decreased in Fgf21-null mice fedMCD for 8 weeks [42]. It is also in-
triguing that Fgf21 disruption suppressed the up-regulation of Pnpla2mRNA in MCD-treated mouse livers. Pnpla2 encodes ATGL, a key
enzyme for TG hydrolysis in the liver [43], and its up-regulation is pre-
sumably an adaptive response to rapid and aberrant accumulation of TG
in hepatocytes. Thus, lower levels of Pnpla2 induction may lead to
delayed TG turnover. Additionally, higher Cd36 and Ppap2a/2c mRNAs
suggest enhanced FA uptake andDAG synthesis in thesemice. Therefore,
reduced fat clearance and increased TG precursors are possible mecha-
nisms for the higher TG accumulation in MCD-treated Fgf21-null mice.
ER is themajor site for TG synthesis from FA andphosphatidate/DAG.
It is well accepted that saturated FA, such as PA, have pro-apoptotic and
cytotoxic properties through inducing ER stress [33,34]. While ER stress
was reported to induce FGF21 [44,45], the relationship between ER
stress, lipotoxicity, and FGF21 induction are incompletely understood.
The present study uncovered PPARα-independent FGF21 induction in
response to PA-induced ER stress in mouse primary hepatocytes, in
addition to greater TG accumulation and ER stress in MCD-treated
Fgf21-null mice. These results indicate that endogenous FGF21 might
be up-regulated in steatotic hepatocytes in order to protect hepatocytes
from increased hepatic lipids and lipid-derived ER stress. Indeed, elevat-
ed serum/liver FGF21 was reported in human NAFLD, and signiﬁcantly
correlated severity of steatosis [25–28]. This is presumably an adaptive
response to limit fat accumulation and ensuing lipotoxicity. Based on
these ﬁndings, therapeutic strategies to achieve robust and continuous
up-regulation of hepatic FGF21 might be beneﬁcial to treat NAFLD.
The interconnection between ER stress, oxidative stress, and inﬂam-
matory signaling leads to hepatocyte injury and progresses steatosis to
steatohepatitis. Recently, it was reported that Fgf21-null mice exhibited
higher levels of serum ALT after MCD feeding for 8 weeks, but not
4 weeks, and increased hepatic TG and malondialdehyde at 8 weeks of
MCD treatment [42]. However, these changes might be a consequence
of persistent disruption of lipid metabolism and activation of
Fig. 9. H2O2, but not tumor necrosis factor α, induces Fgf21 independent of PPARα in mouse primary hepatocytes. (A) H2O2 induces oxidative stress-responsive gene Egr1 and Fgf21
mRNAs. Mouse primary hepatocytes were treated with vehicle (Veh) or H2O2 (150 or 300 μM) for 4 h. Statistical analysis was done using the Dunnet's test. n = 4/group. ***P b 0.001
vs. vehicle-administered hepatocytes. (B) PPARα-independent induction of Fgf21mRNA by H2O2. The same experiment as panel (A) was performed using primary hepatocytes isolated
from Ppara-null mice. Statistical analysis was done using the Dunnet's test. n = 4/group. *P b 0.05, **P b 0.01 vs. vehicle-administered hepatocytes. (C) Tumor necrosis factor α (TNFα)
down-regulates Fgf21mRNA.Mouse primary hepatocytes were treated with vehicle (Veh) or TNFα (100 ng) for 24 h. ThemRNA levels ofNos2 (encoding inducible nitric oxide synthase)
were used as a positive control. Statistical analysis was conducted using the Student's t-test. n = 4–6/group. *P b 0.05, ***P b 0.001 vs. vehicle-administered hepatocytes.
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stage NASH pathologies cannot be assessed in mice under long-term
MCD feeding. The present study revealed that, among the factors pro-
moting steatohepatitis, ER stress was singularly enhanced in Fgf21-
null mice in the early stage of MCD-NASH. This ﬁnding indicates that
ER stress is associated with up-regulation of FGF21 and increased ER
stress is an initial event of progressive MCD-NASH in Fgf21-null mice.
This study showed that H2O2 can induce Fgf21 mRNA independent
of PPARα in mouse hepatocytes. This result is in accordance with the
ﬁnding that administration of APAP, a typical oxidative stress inducer,
results in robust increases in FGF21 [20]. Furthermore, administration
of recombinant FGF21 to Fgf21-null mice treated with APAP or MCD
attenuated oxidative stress and hepatocyte injury [20,42]. These
ﬁndings suggest that endogenous FGF21 is up-regulated in diseased
livers to protect hepatocytes from oxidative stress.
Themechanismbywhich cellular stress induces FGF21 deserves fur-
ther investigation. A recent report demonstrated direct transactivation
of FGF21 by ER stress-activated pathways, such as inositol-requiring
enzyme 1α-transcription factor X-box binding protein 1 and eukaryotic
initiation factor 2α-activating transcription factor 4 axes [45]. Addition-
ally, it was reported that c-Jun N-terminal kinase (JNK) and EGR1 are
activated by oxidative stress and the activation is inhibited by FGF21
administration or overexpression [20,46]. Therefore, FGF21 might be
up-regulated in response to JNK and EGR1 activation in order to attenuate
this activation as a means of feedback inhibition. These observations
indicate the possible contribution of stress-activated transcription
factors in the induction of FGF21.
In conclusion, the present study uncovered a critical role for FGF21
induction in the early stage of MCD-NASH development that functions
to minimize lipid accumulation and ensuing cellular stress in the liver.
FGF21 is not only a potent modulator of glucose/lipid metabolism, but
also a novel and promising hepatoprotectant.Transparency Document
The Transparency document associated with this article can be
found, in the online version.
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